Official Title
Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma
Brief Summary

The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.

Treatment IND/Protocol
Relapsed or Refractory Multiple Myeloma

Drug: Teclistamab
Teclistamab will be administered subcutaneously (SC).
Other Name: JNJ-64007957

Eligibility Criteria

Inclusion Criteria: - Patient diagnosed with Relapsed or Refractory Multiple Myeloma - Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial

Eligibility Gender
Eligibility Age
Minimum: 18 Years

Study Contact

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

Janssen Research & Development, LLC
NCT Number
MeSH Terms
Multiple Myeloma
Neoplasms, Plasma Cell